to strengthen the Expert Committee on the Use of Essential Drugs,
ensuring its independence from external pressures at all times, the use of
science-based criteria for revision and updating, and receipt, when appropriate
and as required, of the necessary inputs from all relevant stakeholders;

to ensure that WHO’s medicines strategy addresses the important
issue of the impact of international trade agreements on access to medicines
and to reflect, in the relevant reports to WHO’s governing bodies,
progress in its comprehensive endeavour;

to advocate the necessary action worldwide to promote market-based
differential pricing for essential medicines between high-, middle-, and
low-income countries, and to provide technical support, especially to
developing countries, to establish drug-pricing policies;

to advocate the concept and policies of essential medicines as a tool
for implementing rational prescription of medicines;

to continue to work on the methodology for computerized databases on
reference prices of essential medicines worldwide;

to pursue all diplomatic and political opportunities aimed at overcoming
barriers to access to essential medicines, collaborating with Member States in
order to make these medicines accessible and affordable to the people who need
them;

to join with and support nongovernmental organizations in the process of
implementing initiatives that are compatible with public health priorities.